USBio Logo

208746 Anti-B. pertussis, Recombinant, Pertactin

Specifications
References
Grade
Highly Purified
Applications
E WB
Accession #
CAA06902.2
Shipping Temp
Blue Ice
Storage Temp
-20°C

Pertussis, also known as the whooping cough, is a highly contagious disease caused by the bacterium Bordetella pertussis. Despite generally high coverage with the DTP and DTaP vaccines, pertussis is one of the leading causes of vaccine-preventable deaths world-wide. Ninety percent of all cases occur in the Third World. It is transmitted by airborne infection. B. pertussis vaccine was first developed in 1920 using whole bacterium. In 1942, the whole-cell pertussis vaccine was combined with diphtheria and tetanus toxoids to generate the first DTP combination vaccine. Whole cell vaccines have some side effects. Acellular pertussis vaccine consisting of purified haemagglutinins (HAs: filamentous HA and leucocytosis- promoting-factor HA), which are secreted by B. pertussis into the culture medium are being using alone or in combination with DTaP (aP represents acellular vaccine). The introduction of acellular pertussis (Pa) vaccines in countries with a low uptake of whole-cell pertussis (Pw) vaccines has led to a dramatic reduction in pertussis disease. Those with three or more components consisting of filamentous hemagglutinin (FHA), pertussis toxin (PT) and pertactin (PRN) are considered to be more effective than one/two-component Pa vaccines that contain only PT or both PT and FHA. Pertactin (PRN or p69 protein) is a highly immunogenic virulence factor of Bordetella pertussis, a bacterium that causes pertussis. Specifically, it is an outer membrane protein that promotes adhesion to tracheal epithelial cells. PRN is purified from Bordetella pertussis and is used for the vaccine production as one of the important components of acellular pertussis vaccine. Pertactin domains are common components of the excreted portion of bacterial autotransporter proteins. The domain is made up of a beta helix of variable length. P.69 is produced as a large (910aa) precursor molecule. It is proteolytically processed at its N and C termini to produce P.69 and P.30, which are located at the cell surface and in the outer membrane, respectively. P.69 contains the amino acid triplet arginine-glycine-aspartic acid (RGD), a sequence motif which functions as a cell-binding site in a number of mammalian proteins, and it has been shown that the P.69 RGD sequence is also involved in adherence to host cells . Like P.69, pertussis toxin is excreted and may be found loosely associated with the outer membrane. Pertussis toxin has numerous biological activities and probably plays a role in hampering the host immune response.

Source
Recombinant protein corresponding to full-length B. pertussis Pertactin, fused to His-tag, expressed in E. coli.
Molecular Weight
~91kD
Applications
Suitable for use in ELISA, Western Blot or applications where native protein is not required. Other applications not tested.
Recommended Dilution
ELISA: coat at 0.1-1ug/ml Western Blot: load 50-200ng/ml and detect with appropriate antibodies Optimal dilutions to be determined by the researcher.
Storage and Stability
May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
Source
E. coli
Purity
Highly Purified (~95%)
Concentration
As reported
Form
Supplied as a liquid in 20mM Tris, pH 8.0, 0.1m sodium chloride, 5mM B-mercaptoethnaol, 0.25M imidazole, 6M GdnHCl.
Important Note
This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
Form
Supplied as a liquid in 20mM Tris, pH 8.0, 0.1m sodium chloride, 5mM B-mercaptoethnaol, 0.25M imidazole, 6M GdnHCl.
Purity
Highly Purified (~95%)
References
1. Charles I (1994) Microbiol. 140, 3301. 2. Charles I (1989) PNAS 86, 3554. 3. Emsley P (1996) N. Eng. J. Med. 334, 341. 4. Kobishc M (1990) Inf. Immun. 58, 352. 5. Leininger EC (1992) Inf. Immun. 60, 2380; 2385. 6. Roberts MJ (1992) Vaccine 10, 43
USBio References
No references available
Conjugates
Pricing
Order
Proceed to Checkout
Cart Summary
ProductSizeListYour PriceQtyExt Price
Subtotal:Subtotal:
Subtotal:Subtotal:
Total Coupon Savings:Total Coupon Savings:()
Your cart is currently empty.
- Coupon Code
Recently Viewed
Contact Us

Visit our technical library or contact our support staff to answer your questions.

Telephone:
1-800-520-3011

Library | Contact

Distributors

For customers outside of the United States, please use one of our many distributors.

View Distributors

Payment Methods

We accept the following payment methods as well as pay-by-invoice.

MasterCard Visa PayPal
© 2023-2024 United States Biological - All Rights Reserved